Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Now with a definitive tie between Urano/wolfram/diabetes/manf/ambs...no dots.
The release of the wolframe documentary with Urano's insights in2014 really could be a nice catalyst to public knowledge of Amarantus.
Actually Retired 4-star general Pete Chiarelli, one of the key speakers at #C4CT and is on the panel to award moneys from the GE-NFL collaboration, Healthy Head Initiative. Awarding $60M over the next several years.
He's also the head of One Mind.
http://www.nfl.com/news/story/0ap1000000223891/printable/genfl-head-health-challenge-continues
IMO.. very impressive growth in the #C4CT arena.
The list of attendees and presenters is impressive with representation not just from academia, but also from NCAA, Players associations, ect. It's shown a lot of growth since last conference in June.
The meeting and movement seems to be gaining traction and is a great event for AMBS to be a part of.
Nice to see you back warp. I remember your posts from about this time last year. Thought they had given you the permanent boot from the board.
I too have added and brought my avg down during the last few months. My sharecount is a shadow of yours, but thoughts are the same that 2014....and beyond will prove to be groundbreaking for AMBS.
Upcoming #C4CT summit info of presenters, ect..
https://classic.regonline.com/builder/site/tab1.aspx?EventID=1269518
Check the facebook site. Funding was completed and the film is "in the can" as they say in that field. Release is expected mid 2014.
Btw. Concerning hope of a correlation in treatments in type 1 and type 2.......have to expect that an expert in the field like Urano would know better than you, no?
Dr Urano to be in documentary short film "A Light in the Shadows" addressing Wolfram Syndrome
http://www.wolframmovie.com/sample-page
In film Dr. Urano will be providing key insights to disorder and progress towards a cure.
Belief is that a cure for Wolfram could lead to a cure for diabetes as a whole.
This movie will be huge for Wolfram awareness considering the back story(see link). If MANF can be a part of the cure as Urano is working on....this will be a catalyst of huge proportions.
Actually good find. Here's the source page of the photo..
http://www.thesnowfoundation.org/research/2013-wolfram-clinic/
Download Urano's presentation slides for 2013 Wolfram Clinic Research Update
Interesting mentions of MANF and progress of his studies into Wolfram...
Just to be sure that a misunderstood statement doesn't lead to a false rumor.....cause that never happens here, right?
Are we absolutely sure that the TBI conference is presenting "to the General Assembly?
My dd suggests that the UN wraps up the current session by the end of December. The only Amarantus issued PR specifically said "at" the UN and not "to" the UN.
Does anyone have any other confirmation of this?
Has anyone else done the dd to know who dr. . J actually is except me? Seriously? Perhaps they should dd the credibility of another "dr" Who posts/mods here first...
We've had a lot of telegraphed pre-opening pops.. for flippers to sell into over the last few months. Hope today is different and the gap is from new investors...perhaps from yesterday's conference.
My understanding would be that "intellectual property" is referring the patent protected application and uses filing made by University of Miami.
http://patentscope.wipo.int/search/en/detail.jsf?docId=WO2012170918&recNum=2&office=&queryString=FP%3A%28mesencephalic+astrocyte-derived+neurotrophic+factor%29&prevFilter=&sortOption=Pub+Date+Desc&maxRec=2
"The present invention provides methods of treating a retinal disorder comprising administering an effective amount of a neurotrophic factor to a subject having the retinal disorder. The neurotrophic factors useful in the invention include mesencephalic astrocyte-derived neurotrophic factor (MANF) and conserved dopamine neurotrophic factor (CDNF). The present invention further comprises pharmaceutical compositions and kits containing MANF and CDNF."
Would you mind reposting this......everyday. 100% agree.
Something could be mentioned by Marks, but doubtful for the same reasons that Gerald wouldn't comment on any ongoing relations with MJFF. Marks was part of the MJFF Neurotrophic Factors discussion earlier this year and nothing was mentioned specifically about MANF....although that was the discussion where a "cocktail" therapeutic approach was a consideration.
What is more important in my mind is that:
"Amarantus has a relationship with Renishaw through a grant application with the Michael J. Fox Foundation, so it would not surprise us to see Amarantus team up with Renishaw later this year."
From Jason's AMBS Zack's Report, 5/22/13, pg. 13
This is not dot connecting...just the facts-
-LOI has been signed with Renishaw for CED delivery
-MJFF grant application for CED/MANF research has been submitted
-
This is dot connecting and positive speculation...
-MJFF is not done with Amarantus/MANF
On May 22, 2013, the Company entered into a letter of intent to in-license a Phase 2 drug candidate in L-Dopa-Induced Dyskinesia Parkinson's Disease from an undisclosed third party. Once licensed the Company intends to initiate a Phase 2b clinical trial within 12 months. June 13, 2013 8k ...Eltoprazine
-Previous recipient of this program was Psychogenics with their work with Eltoprazine
-New board member David Lowe...with ties to Psychogenics.
-4th quarter MJFF Partnering Program awards are due any day.
Adding to position tomorrow, you?
These patents for applications of the MANF protein just keep popping up... I guess the pump and dump artists have them fooled too??
Patent published 8/21/2013 by Suzhou Institute of Tongji University Housing Jianmin
A recombinant fusion protein TAT-MANF and its application
. Using this method has been efficiently EGFP, ß- galactosidase , insulin and other proteins to the cells, or through the blood-brain barrier .
SUMMARY OF THE INVENTION
The present invention is to solve the technical problem of providing a recombinant fusion protein TAT-MANF and application of the recombinant fusion protein TAT-MANF across the cell membrane into the cell and play a good protective effect of nerve cells can slow Parkinson disease -related neuron disease , is a new type of medicine and good biotech drugs .
The present invention is a recombinant fusion protein TAT-MANF , is caused by human immunodeficiency virus trans-activator TAT protein transduction protein transduction domain of the fusion protein to form modified MANF , which sequence comprises the amino terminus of the TAT sequence and is located in a carboxyl group MANF end sequence . TAT sequence of SEQ ID NO: 1 shows the sequence or a variant or truncated sequences. The MANF sequence as SEQ ID NO: 2 shows the sequence or a variant or truncated sequences.
The present invention provides such a fusion protein by the TAT protein transduction domain and MANF composition , the present invention patent application is called TAT-MANF fusion protein fusion protein .
Recombinant TAT-MANF fusion protein contains two functional areas, each functional area functions as follows : TAT protein transduction domain is a basic amino acid -rich peptide fragments , the main function is to guide the fusion protein recombinant TAT-MANF penetrate the cell membrane . MANF main function is to promote the survival of dopaminergic neurons or rebuild the normal function of the dopaminergic nervous system , Parkinson's disease and dopamine as neuronal injury is closely related to the present invention, recombinant TAT-MANF fusion proteins can be used for the treatment of Parkinson's disease .
http://patentscope.wipo.int/search/en/detail.jsf?docId=CN92028786&recNum=1&office=&queryString=FP%3A%28manf%29&prevFilter=&sortOption=Pub+Date+Desc&maxRec=31
Yep, it's in Chinese...cut and paste into google translator...
Honest question though, this is an application of MANF or variation of, correct? Not a new protein?
You are a licensed physician?
Just general info on the topic...
Focus of the patent filed by UMass involving MANF is at B-cell disorders in general. Some of these are not uncommon such as Type 2 diabetes, while others are very rare, such as congenital hyperinsulinism. One source I found referred to this as "anti-diabetes."
Since you brought up the topic of the new investors from the S-1...,have you seen these two "losers"(sarcasm infused) who were included...
-ROBERT F. JOHNSTON-Warrants for over 8.5 Million AMBS shares: Bob Johnston founded Johnston Associates Inc. in 1968 to provide merger advisory and financing for emerging companies in technology-intensive industries. In the mid-70s, he directed his efforts toward biotechnology and health care. He founded Cytogen, Ecogen, Sepracor, i-STAT, Envirogen, and Praelux (formerly SEQ), and was instrumental in the early formations of Sonomed, Biocyte, Immunicon, and VelaPharm. Prior to starting Johnston Associates, Bob was an investment banker for F.S. Smithers & Co. and for Smith Barney & Co. in New York. He received his B.A. from Princeton University and his M.B.A. from New York University.
BILAL BASRAI Managing Director - Investment Banking at Zack's -also listed on the S-1 as issued warrants for almost 6,000,000 AMBS shares.
Bilal Basrai is the Managing Director and head of investment banking at Zacks & Company, where he oversees the firm’s investment banking and capital markets efforts. Prior to joining Zacks, Bilal was most recently Director of the Corporate Finance Group at C.K. Cooper & Company, a research-driven, institution-focused, investment banking boutique, providing the full range of capital market and advisory services to public and private companies. At C.K. Cooper & Company, he was the team leader on corporate finance assignments with the firm’s Healthcare clients, which included appraisals, fairness opinions, merger and acquisition advice, licensing agreements and capital formation.
Bilal spent the majority of his career in New York City covering the Health Care Services sector with leading investment banks including Salomon Smith Barney, UBS Financial, and Lehman Brothers. He also spent two years with the Stanford Financial Group in South Florida, prior to co-founding Iliad Advisors, LLC in 2006, a boutique investment advisory firm. Bilal has been involved in over $4.5 billion worth of transactions in the Healthcare sector over his Wall Street career.
Bilal has also been a top-ranked analyst for the majority of the Healthcare stocks that he has covered during his days as an equity research analyst and has generated an excess industry return of 11.1%, according to analyst ranking agency Starmine Monitor. The agency has ranked him as the seventh best stock-picker in the Healthcare Services & Providers Industry
Not too shabby, huh?
Nice posting of the significance of yesterday's news.
http://www.ucsf.edu/news/2013/10/109986/media-advisory-qb3-and-city-celebrate-launch-new-bioscience-incubator
Curious to me is that Ono is providing the funding for Urano's MANF/diabetes research at UMass with knowledge that under collaborative agreement between Amarantus and the University of Massachusetts stated earlier, the licensing rights would belong to AMBS...
So help me understand this...IF the"invention made solely by one or more employees of the University of Massachusetts will belong to the University..
but, "Should the University of Massachusetts obtain a patent on an invention it created from the Study, Amarantus has licensing rights under the terms of the Agreement between Amarantus and the University"...
What exactly does that mean to Amarantus? ...not a "loaded question." Just really trying to understand potential/implications...
Pancreatic beta cell disorders...
Some more interesting "dots"...
This was filed by URANO, Fumihiko (the lead investigator of the ONO Pharm grant study at UMASS)....UMASS who is also working on other applications for MANF with Pioneer Valley Life Sciences, lead by Lawrence M. Schwartz, PhD...who is on the Amarantis Scientific advisory board...
SOLUBLE MANF IN PANCREATIC BETA-CELL DISORDERS
http://patentscope.wipo.int/search/en/detail.jsf?docId=WO2013112602&recNum=1&maxRec=8&office=&prevFilter=&sortOption=Pub+Date+Desc&queryString=ALLNAMES%3A%28+%09Fumihiko+Urano%29&tab=PCT+Biblio
Lol! Agree. #5 has my vote as well. Already has MJFF vote.....
For whatever it's worth, I think his comment was referring to a question I, and perhaps others, sent in. I got registered early enough for the webinar to be able to forward Q's for possible response at the end of the webinar.
Not sure of others, but for myself, my question was fairly open ended trying to dig for intentions in continued focus on neurotrophic factors given the very recent(at the time) Ceregene/Neuturin disappointing results. I thought his comments were very promising.
Ironically also at the summitt today is Dr. Reese of "Provista Diagnostics/" Sound familiar? This is a spinoff of Memory Dx focusing on their breast cancer diagnostic. Isn't this is the company that AMBS licensed Lympro from for a VERY low price considering its potential.
Say what you will about the delays in announcements, lack of partnership deal, increase potential of dilution to increase coffers, thus benefiting a stronger position to negotiate from....but possibly Gerald has already shown he knows how to enter and leave a negotiation on top.
Finally! Someone said it! If they have the goods, a rs just gets us out of the otc jungle. Majority of rs horror stories are from co that used it to try and salvage their downward slide and stay in their current exchange or to continue their diluting rippoff of shareholders. AMBS is neither of these.
Agenda for tomorrows Summitt posted for review..
http://livingstonsecurities.com/PDF/Agenda.pdf
Strange? Only other company I can find indicating they are presenting at the Livingston Summit tomorrow is Boston Therapeutics, group with a phase II diabetes treatment candidate and an anti-aptosis?? ischemic condition compound in preclinical development.
No one else coming to this party?
Full disclosure on that quote before someone decides to pick it apart...was not from the AMBS PR, but rather from a past PR from Livingston about the nature of the Life Science Summit.
Bu I agree, doesn't appear to be the typical "you pay a hefty registration fee to participate" event.
Livingston Securities focuses on providing investment banking, advisory and brokerage services to a wide variety of clients, including public and private corporations, institutional and high net worth investors, governments and universities.
"This is a unique, by invitation conference, designed to bring together key stakeholders from pharmaceutical, finance and investment, business strategy, as well as governmental science and regulatory segments, according to Conference Chair, Mostafa Analoui, PhD, Head of Healthcare and Life Sciences at Livingston Securities."
BILAL BASRAI Managing Director - Investment Banking at Zack's -also listed on the S-1 as issued warrants for almost 6,000,000 shares.
Bilal Basrai is the Managing Director and head of investment banking at Zacks & Company, where he oversees the firm’s investment banking and capital markets efforts. Prior to joining Zacks, Bilal was most recently Director of the Corporate Finance Group at C.K. Cooper & Company, a research-driven, institution-focused, investment banking boutique, providing the full range of capital market and advisory services to public and private companies. At C.K. Cooper & Company, he was the team leader on corporate finance assignments with the firm’s Healthcare clients, which included appraisals, fairness opinions, merger and acquisition advice, licensing agreements and capital formation.
Bilal spent the majority of his career in New York City covering the Health Care Services sector with leading investment banks including Salomon Smith Barney, UBS Financial, and Lehman Brothers. He also spent two years with the Stanford Financial Group in South Florida, prior to co-founding Iliad Advisors, LLC in 2006, a boutique investment advisory firm. Bilal has been involved in over $4.5 billion worth of transactions in the Healthcare sector over his Wall Street career.
Bilal has also been a top-ranked analyst for the majority of the Healthcare stocks that he has covered during his days as an equity research analyst and has generated an excess industry return of 11.1%, according to analyst ranking agency Starmine Monitor. The agency has ranked him as the seventh best stock-picker in the Healthcare Services & Providers Industry
Does anyone really think that investors like Basrai and Johnston are getting involved to dump shares at .10....c'mon?
Here's an interesting new AMBS connection..per the S-1, this guy was issued warrants for over 8.5million shares. While it is, as some have said, a "sweetheart deal", this is only if the pps rises above .10 for the pre-set period of time. Seems promising that someone of this status would invest a sizable amount in AMBS, yes?
ROBERT F. JOHNSTON: Bob Johnston founded Johnston Associates Inc. in 1968 to provide merger advisory and financing for emerging companies in technology-intensive industries. In the mid-70s, he directed his efforts toward biotechnology and health care. He founded Cytogen, Ecogen, Sepracor, i-STAT, Envirogen, and Praelux (formerly SEQ), and was instrumental in the early formations of Sonomed, Biocyte, Immunicon, and VelaPharm. Prior to starting Johnston Associates, Bob was an investment banker for F.S. Smithers & Co. and for Smith Barney & Co. in New York. He received his B.A. from Princeton University and his M.B.A. from New York University.
http://www.jaivc.com/bio.html
Check out his list of current and previous portfolio companies...
It seems the point to contest is "long."
I can only assume 99.99% of have been invested no longer than 12-14 month....Most probably significantly less than that.
I could be wrong...there may be a true early bird out there somewhere.
The definition of "long" seems to vary by individual. It seems may "longs" are frustrated because pp hasn't allowed for them to pull their initial investment out to ride free shares yet.....not sure that's really a "long" investment strategy...IMO.
News this week is the expectation...why all the bashing now that we are 45 minutes into a 32.5 hour trading week?
We all know why, just pointing out the obvious...
He makes it too easy to follow. All of his handles are Bob Dylan song related. Must be a big fan....
Hey maybe we should all start slamming Dylan the way he slanders AMBS/Gerald!! That'l send him over the edge
Not trying to throw insults tech, just pointing out that a ceo's age may not be the important factor in todays business u are suggesting. And only mentioned the football to beat someone to the punch of insulting Gerald's intelligence as a link to his athletic ability.... As has been done countless times on this board. Awful lot of ex pro/college athlete business world success stories out there too..
Pick up a paper or read any business/entrepreneur mag... Please.
Age? Really? That's the focus point now? Holy sxxt that's empty. No successful ceos under 31 out there? Really? No brilliant entrepreneurs under 31? And gerald, he played sports too, so he can't be very smart. Do you realize how xxxxxxx that sounds?
Must have been a Scottrade hiccup. the transaction just cleared, but the time stamp was back at 9:43. Strange.